Merck Stock News

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE: MRK ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with MRK, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 17 uncommon options trades for Merck & Co. This isn''t normal. The overall sentiment of these big-money traders is split between 29% bullish and 70%, bearish. Out of all of the special options we uncovered, 4 are puts, for a total amount of $134,404, and 13 are calls, for a total … Full story available on Benzinga.com

Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity

Profit and loss experience is critical to career development, and Paradigm for Parity is launching a program aiming to close that gap for women of color. Read More

Read more Merck Came Into Today Down -0.55% The post Merck Came Into Today Down -0.55% appeared first on CFDTrading .

The Conjugate Vaccine Market research report provides an in-depth overview of the industry including market segmentation by product, technology, vertical and geography. Analysis of the global market with special focus on high growth application in each vertical and fast-growing application

Chiral HPLC Column-Global Market Status & Trend Report 2018-2028 Top 20 Countries Data offers a comprehensive analysis on Chiral HPLC Column industry, standing on the readers perspective, delivering detailed market data in Global major 20 countries and penetrating insights pune, Maharashtra -- ( SBWIRE ) -- 02/21/2022 -- Summary A New Market Study, Titled "Chiral HPLC Column Market Upcoming Trends, Growth Drivers and Challenges" has been featured on fusionmarketresearch. This report provides in-depth study of ''Chiral HPLC Column Market ''using SWOT analysis i.e. strength, weakness, opportunity and threat to Organization. Chiral HPLC Column report also provides an in-depth survey of major market players which is based on the various objectives of an organization such as profiling, product outline, production quantity, raw material required, and production. The financial health of the organization. Sample Request @ https://www.fusionmarketresearch.com/sample_request/Chiral-HPLC-Column-Global-Market-Status-and-Trend-Report/82441 Chiral HPLC Column-Global Market Status & Trend Report 2018-2028 Top 20 Countries Data offers a comprehensive analysis on Chiral HPLC Column industry, standing on the readers'' perspective, delivering detailed market data in Global major 20 countries and penetrating insights.

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Gene Synthesis Market finds that rising prevalence of infectious diseases as well as chronic diseases is expediting market growth. Primarily driven by high efficiency, the total Global Gene Synthesis Market is estimated to reach USD 6.58 Billion by 2028, up from USD 2.16 Billion in 2021, at a compound annual growth rate (CAGR) of 17.9%. Furthermore, supportive government policies associated with synthetic biology and surging investments from government as well as major players to augment the growth of the Global Gene Synthesis Market, states Vantage Market Research, in a report, titled " Gene Synthesis Market by End User (Academic and Research Institutes, Biopharmaceutical Companies, Contract Research Organizations), by Method (Oligonucleotide Synthesis, Gene Assembly), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Experts are predicting demand for life-saving antiviral drugs will rapidly outpace supply. Like the vaccine, the poorest countries will be left until last Covid-19 has quietly become the gift that keeps on giving for big pharma. The past two years has seen it reap huge profits from Covid vaccines, while simultaneously opposing wider sharing of the technology required to make them. And now theres a new money-spinner on the rise: Covid antiviral treatment pills. Once again, were poised to fall into the same inequality traps were caught in with the global vaccine rollout. Both Pfizer and Merck have new antiviral pills rapidly arriving on the market Paxlovid and molnupiravir respectively. As with the vaccines that came before them, both corporations have made it their business to ultimately decide who gets to make generic versions through the medical patent system a crucial, life-saving question for millions around the world. Othoman Mellouk is a medicine access advocate with the International Treatment Preparedness Coalition Continue reading.

The antiviral pill molnupiravir reduced the risk of COVID-19 hospitalisation by 65% in a new study by Indian researchers that offered stronger resu

After disappointing trial results led to canceled orders, an encouraging new study may give Merck''s anti-Covid pill a new boost.

Merck KGaA (MKKGY) said long term data showed overall survival benefit of Bavencio (avelumab)as first-line maintenance treatment in patients with advanced urothelial carcinoma, a type…

South Africas health products regulator said on Friday it had approved the use of Mercks Covid-19 pill for high-risk adults

Organon topped fourth-quarter estimates Thursday, but OGN stock fell on lighter-than-expected 2022 sales guidance.

JOHANNESBURG — South Africa’s health regulator SAHPRA said on Thursday that it had authorized use of Merck’s COVID-19 treatment pill molnupiravir. SAHPRA added in a statement that Pfizer had submitted an application for its COVID-19 pill, Paxlovid, which was under consideration. “The authorisation of molnupiravir for compassionate use offers further therapy in the fight against […]

JOHANNESBURG — South Africa’s health regulator SAHPRA said on Thursday that it had authorized access to Merck’s COVID-19 treatment pill molnupiravir. “The authorisation of molnupiravir for compassionate use offers further therapy in the fight against COVID-19,” SAHPRA said in a statement. (Reporting by Alexander Winning Editing by Tim Cocks)